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Abstract The aim of this review article is to evaluate the
current knowledge on associations between muscle for-
mation and regeneration and components of the nuclear
lamina. Lamins and their partners have become particularly
intriguing objects of scientific interest since it has been
observed that mutations in genes coding for these proteins
lead to a wide range of diseases called laminopathies. For
over the last 10 years, various laboratories worldwide have
tried to explain the pathogenesis of these rare disorders.
Analyses of the distinct aspects of laminopathies resulted
in formulation of different hypotheses regarding the
mechanisms of the development of these diseases. In the
light of recent discoveries, A-type lamins—the main
building blocks of the nuclear lamina—together with other
key elements, such as emerin, LAP2a and nesprins, seem
to be of great importance in the modulation of various
signaling pathways responsible for cellular differentiation
and proliferation.
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Introduction
Muscle degenerative disorders, characterized by the pro-
gressive loss of muscle strength and integrity, affect a
significant part of the human population. The genetic basis
of these diseases is very diverse. Muscular dystrophies are
caused by the mutations in different genes encoding a wide
variety of proteins such as extracellular matrix proteins,
transmembrane and membrane-associated proteins, nuclear
proteins and cytoplasmatic enzymes [108]. In this article,
we focused on the muscular dystrophies which belong to
the laminopathies and are connected with the nuclear
proteins. The term laminopathies defines a group of dis-
eases associated with mutations in the genes coding for
lamins, proteins associated with their post-translational
processing, or proteins interacting with the lamins [249,
250], also refer: [255]. As indicated by several studies,
such mutations may affect development of tissues of
mesodermal origin, mostly muscles and its regeneration
[142]. In the light of these discoveries, it is essential for us
to analyze current data and try to understand the underlying
molecular mechanisms responsible for the involvement of
lamins and their partners in myogenic processes. We
focused on molecular mechanisms and pathways which are
or may be affected by mutations in genes coding for
nuclear envelope proteins.
Lamins
The cell nucleus is separated from the cytoplasm by the
nuclear envelope (NE), composed of the nuclear lamina
(NL), an outer and inner nuclear membrane (ONM and
INM, respectively), connected in the region of nuclear pore
complexes (NPC). The NL is composed of lamins, which
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are type V intermediate filament proteins and are grouped
into A- and B-types based on their biochemical properties,
post-translational modifications and behavior during mito-
sis. Lamins are present in the nuclear interior as well [30].
They are expressed in all studied metazoans but are absent
from yeast and plants. Three genes encode lamins in
humans: LMNA for A-type lamins (lamin A, C and other
isoforms like lamin C2, lamin AD10) [131], LMNB1 for
lamin B1, and LMNB2 for lamin B2 [99, 131]. It is com-
monly known that in contrast to B-type lamins, which are
ubiquitously produced in all cell types during embryonic
and adult life, A-type lamins are highly expressed in dif-
ferentiated tissues, particularly in skeletal muscle and in
some adult stem cells, including mesenchymal stem cells,
hair stem cells and satellite cells. A-type lamins are absent
in other types of stem cells, including embryonic stem cells
[205]. A-type lamins are not essential for cell proliferation.
They play a crucial role in the exit from the cell cycle [75].
Apart from expression patterns, lamins differ in terms of
the presence of a farnesyl tail. Lamins A and B terminate
with a CaaX motif (where C is a cysteine, a is an aliphatic
amino acid, and X is often hydrophobic residues). The
maturation of lamins requires sequential enzymatic modi-
fications of this motif: farnesylation, proteolytic cleavage
and carboxy-methylation. B-type lamins retain farnesyla-
tion, whereas in the case of lamin A (lamin C does not have
a farnesylation motif) [219] the farnesyl tail is clipped off
by zinc metalloproteinase ZMPSTE24 [17]. The structure
of all types of lamins is very similar and related to their
cytoplasmic intermediate filament homologues: a con-
served central a-helical rod domain containing four
segments—1A, 1B, 2A and 2B—is flanked by two variable
globular domains (the N-terminal head domain and the
C-terminal tail domain) [2].
Most scientists agree that one of the main functions of
lamins are to provide structural support to the nucleus,
maintenance of nuclear shape and spacing of NPC. Over
the years, numerous reports have suggested that lamins also
take part in other process: chromatin organization, DNA
replication, epigenetics, transcription, cell cycle regulation,
cell development and differentiation, nuclear migration,
and apoptosis [193]. Lamins together with integral mem-
brane proteins of NE and associated proteins participate in
the regulation of chromatin organization [220] and for-
mation of chromatin microdomains associated with NE
[49, 141]. Although the necessity of B-type lamins in
certain cell functions has been recently challenged [111,
253].
Lamins do not play all of those functions alone but by
interaction with many other proteins of NE and nuclear
interior as well. Major group of proteins interacting with
lamins belong to LEM domain proteins: LAP2 proteins,
emerin and MAN1 (LEMD3), LEM2/NET25 protein.
Lamins also interact with LAP1 proteins, LBR, SUN pro-
teins, pRb, MLIP, NET39, actin, cyclin D3, cFos, Oct-1,
SREBP1, MOK2, ING1, PKCa, JIL-1 and BicaudalD
protein. Lamins may also possibly interact with predicted
membrane proteins: LEM3, LEM4, and LEM5. Lamins can
bind nucleic acids, chromatin and histones in vitro and
DNA and chromatin in vivo (see [209, 256]. Lamins and
protein complexes containing lamins can affect transcrip-
tion through different mechanisms [261].
Laminopathies: the involvement of lamins and
lamina-associated proteins in development,
maintenance and regeneration of muscle tissue
Laminopathies typically not only affect one tissues in
isolated fashion, or several tissues in a generalized way
(premature ageing syndromes—systemic laminopathies),
but have also overlapping phenotypes. Based on the
affected tissue, laminopathies can be classified into several
categories: lipodystrophies, neuropathies, dermopathies,
cardiomyopathies and muscular dystrophies [137, 248,
255]. The most common group is laminopathies of the
muscular dystrophy type, which is the focus of this study.
The first reports on laminopathies appeared in the 1990s
and described the X-linked recessive form of Emery–
Dreifuss muscular dystrophy (EDMD1, XL-EDMD;
OMIM 31300). Since then, a growing number of research
papers on related diseases have appeared, some of them
affect solely muscle tissues. Following are some of such
diseases: autosomal dominant form of EDMD (EDMD2,
AD-EDMD; OMIM 181350) [23] autosomal recessive
EDMD (EDMD3, AR-EDMD; OMIM 604929), cardio-
myopathy dilated 1A (CMD1A; OMIM 115200) [31],
limb-girdle muscular dystrophy type 1B (LGMD1B;
OMIM 159001) [165] congenital-type muscular dystrophy
(OMIM 613205) [158] and ‘‘heart-hand’’ syndrome (HHS;
OMIM 610140) [198] All mentioned diseases are caused
by the mutations in LMNA gene, and have different clinical
phenotypes. EDMD is characterized by the clinical triad of
slow progressive muscle wasting, cardiac conduction
defects, and contractures at the elbows, ankles and neck
[79]. LGMD1B appears during the first 20 years of life and
is characterized by weakening of the shoulder and pelvic
girdle musculature, age-related atrioventricular cardiac
conduction disturbances, and dilated cardiomyopathy
[165]. Dilated cardiomyopathy is a disorder which causes
atrial fibrillation and cardiac arrest. Heart-hand syndrome
is characterized by the association of congenital cardiac
disease and limb deformities [203]. Moreover, the litera-
ture also describes heterogeneous clinical cases suggesting
an overlapping continuum with different types of lamin-
opathies. For example, patients with clinical features of
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lipodystrophy also exhibit cardiac and skeletal muscular
alterations [236], one report describes a patient with fea-
tures of myopathy and peripheral neuropathy [18].
It is challenging to explain the mechanisms by which
mutant lamins contribute to the tissue-specific pathology,
while A-type lamins are expressed in all or many differ-
entiated somatic cell types. According to recent
knowledge, three hypotheses have been postulated to
explain how mutations in the LMNA gene cause tissue-
specific diseases for example muscular dystrophies.
The so-called structural hypothesis assumes that
mutations in A-type lamins alter NL integrity, leading to
its structural weakness, which finally results in decrease
in the ability of nucleus to resist high mechanical stress
within cells, particularly within skeletal muscles [32, 122,
223].
The gene-expression model hypothesis assumes that,
mutations in the LMNA gene alter regulation of gene
expression during differentiation of tissues of mesodermal
origin, especially muscles. This may also cause the dis-
ruption of the balance between muscle degeneration and
renewal [53, 75]. The mechanism by which gene expres-
sion is regulated by the NE is based on direct interactions
of A-type lamins and associated proteins with different
transcription factors and chromatin modifying complexes.
[7]. A-type lamins play an important role in the muscle by
influencing the expression of genes necessary for muscle
cells differentiation. Several studies undertaken over the
past few years support the gene-expression model,
including the investigations of associations of A-type
lamins and their partners (e.g. LAP2a) with transcription
factors, such as Rb protein [144]. Changes in mRNA
expression were observed for patients with laminopathy
[57]. Myoblasts with reduced lamin A/C or emerin are
characterized by reduced levels of proteins important for
muscle cells: MyoD, desmin, pRb, and M-cadherin [75].
Recently, it has also been shown that microRNA (short
RNA molecules that regulate gene expression by binding to
target mRNAs) transcriptome is affected in laminopathy
patients [224]. MicroRNAs play a crucial role in cardiac
and skeletal muscle function. Some miRNAs are highly
expressed in striated muscles, where they control the pro-
liferation and differentiation balance [46]. Moreover, it is
known that nucleoplasmic lamins colocalize with RNA
splicing factor [120].
Some authors suggest a third, ‘‘combined theory’’ which
connects both hypotheses [75, 145]. There are also other
hypothesis that propose that lamins regulate tissue
homeostasis, and lamin mutants impair adult stem cell
function [85].
Laminopathies are mainly attributed to mutations in the
LMNA gene [255]. However, more recently two disorders
have been linked to mutations in genes encoding B-type
lamins: adult-onset autosomal dominant leukodystrophy
and (ADLD, OMIM 169500) [183] and acquired partial
lipodystrophy (APL, OMIM 608709) [95]. New studies
also brought the evidence linking some disease phenotypes
with mutations in genes coding for ZMPSTE24 (an enzyme
processing A lamins) and various proteins interacting with
lamins e.g. emerin, MAN1 (LEMD3), LBR, nesprin-1 and
nesprin-2 [147]. Mutations in this gene can cause diseases
with highly overlapping clinical features to laminopathies.
For example, XL-EDMD caused by mutations in the EDM
gene coding for emerin, has a very similar phenotype to
AD-EDMD caused by LMNA mutations.
In recent studies, the mutual influence of emerin and
lamin A precursors has been observed [41, 125]. The lack of
emerin disturbs the localization of prelamin A, which sub-
sequently leads to perturbation in the mature lamina and
chromatin organization, whereas emerin localization is
affected by the accumulation of non-farnesylated and
farnesylated carboxymethylated prelamin A. In cells from
patients affected by EDMD1, in spite of normal lamin A
processing, the impaired localization of non-farnesylated
prelamin A was observed. In these cells, exogenous
expression of emerin restored the normal distribution of
lamin A precursor [41, 125]. Similar results were obtained
for fibroblasts from EDMD2 patients in whom non-farn-
esylated prelamin A was mislocalized [143]. In EDMD2
with loss of lamin A protein expression, redistribution of
emerin from nucleus to endoplasmic reticulum (ER) occurs
[177]. Loss of emerin from the nuclear envelope also occurs
in lamin A/C-null mouse fibroblasts [223], which results in
aberrant signal transduction. Interactions between emerin
and prelamin A may be of great importance for chromatin
organization due to their associations with proteins: het-
erochromatin protein 1 (HP1), LAP2a and BAF, which are
known to build a complex that regulates chromatin
dynamics and remodeling [41, 125, 143]. This is particu-
larly important during myogenic differentiation when large-
scale chromatin reorganization takes place [29].
Phenotypes similar to EDMD are also associated with
mutations in the SYNE1 and SYNE2 genes, encoding ne-
sprin-1 and nesprin-2. Nesprins are giant proteins (up to 1
MDa) and contain a C-terminal KASH domain, a small,
conservative region interacting with the C-terminal SUN
domain of SUN proteins in the perinuclear space. A-type
lamins, emerin, nesprins (also known as syne, myne,
nuance, enaptin) and SUN proteins participate in the LINC
(linker of nucleoskeleton and cytoskeleton) complex,
which is responsible for linking the nucleoskeleton with the
cytoskeleton [56]. Localization of the nesprins in the NE
depends on SUN proteins, which in turn are positioned in
the nuclear membrane due to their associations with A-type
lamins. One of the nesprin short forms, nesprin-1a, is a
product of alternative splicing and is highly expressed in
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cardiac and skeletal muscles [92, 184, 243]. All mentioned
elements of the LINC structure have additional binding
partners that enable them to play important roles in the
maintenance of cellular function, e.g. control of signal
transduction, response to mechanical stress and positioning
the nucleus within the cell [56]. It is worth mentioning that
only mutations in LMNA that cause muscle diseases affect
the LINC complex anchoring function of lamin A/C [74].
Three major proteins interacting with lamins (all LAP2
isoforms, emerin and MAN1) are members of a family
defined by a 43-residue LEM domain near the N-terminus,
which is involved in binding to a chromosomal protein,
barrier to autointegration factor (BAF)—a small protein
with a role in higher order chromatin structure [249, 255].
BAF mutations cause a progeroid syndrome that is a very
similar to laminopathy Hutchinson–Gilford progeria syn-
drome (HGPS) [196].
Among newly identified NE-associated polypeptides,
muscle-enriched A-type lamin-interacting protein (MLIP)
[5] and NL-associated NE transmembrane protein (NET39)
should be mentioned [132]. MLIP, whose nuclear locali-
zation and expression depend on lamin A, is expressed
abundantly in skeletal and smooth muscles and may con-
tribute to the mesenchymal phenotypes of laminopathies.
MLIP co-localizes with PML protein in PML bodies engaged
in the processes such as post-translational modifications,
transcriptional regulation, DNA damage responses, and
apoptosis [5]. NET39 is also highly expressed in skeletal and
cardiac muscles and participates in muscle homeostasis and
regeneration [132].
Lamins interact with nuclear F-actin. It has been
reported that two EDMD-causing mutations in lamin A
significantly reduced such binding, which impact the con-
centration of the actin in the nucleus and influence
processes that require actin (transcription, chromatin
remodeling) [218].
To study the role of A-type lamins, several mouse
models have been created. Loss of A-type lamins results in
growth retardation, developmental defects of the heart,
skeletal muscle hypotrophy, decreased subcutaneous adi-
pose tissue and decreased adipogenic differentiation. Such
mice develop a form of muscular dystrophy closely
resembling EDMD and die from cardiac and skeletal
myopathies, usually 8 weeks after birth [119, 223].
Dr. Bonne’s group [10] developed a mice line which
carries a missense mutation, causing a histidine-to-proline
substitution at position 222 (H222P), originally identified
in patients with AD-EDMD. Described animals exhibit
overtly normal embryonic development, while for adult
individuals scientist observed reduced locomotion, devel-
opment of cardiac fibrosis, chamber dilation, and
hypokinesia with conduction defects. Female homozygotes
exhibit pathologies at a later stage and survive longer than
males, which die 9 months after birth [10]. Other mice
lines described in the literature carry mutation-causing
asparagine to lysine substitution at position 195 (N195K)
(which causes DCM in humans). Such mice die at an early
age due to arrhythmia but also develop severe dilated
cardiomyopathy, similar to the human patients [164]. To
study the effects of expression of lamin A with the M371K
substitution (causes EDMD in humans), a transgenic mice
specifically expressing this protein in heart was generated.
Noteworthy is the expression of this mutant lamin A in
mice, that simultaneously express also endogenous wild-
type A-type lamins, caused cardiac pathology (disruption
of the cardiomyocytes and abnormal nuclei were
observed). Mice were born at lower numbers than that
expected, and those born died 2–7 weeks after birth [241].
The knock-in mouse model Lmna(DeltaK32) exhibited
striated muscle maturation delay and metabolic defects,
including reduced adipose tissue and hypoglycemia leading
to premature death. The level of mutant proteins was
markedly lower in Lmna(DeltaK32/DeltaK32), and while
wild-type lamin A/C proteins were progressively relocated
from nucleoplasmic foci to the nuclear rim during embry-
onic development, mutant proteins were maintained in
nucleoplasmic foci. In the liver and during adipocyte dif-
ferentiation, expression of DeltaK32-lamin A/C altered
sterol regulatory element binding protein 1 (SREBP-1)
transcriptional activities which was essential for tissue
maturation [20].
Cultured myoblasts from Emd null mice revealed
abnormalities in the cell cycle and differentiation process,
but such animals do not develop muscular dystrophy or
cardiac conduction defects, and only muscle regeneration
revealed some defects [155, 182].
Scientists also developed Drosophila melanogaster as a
model to study tissue-specific functions of A-type lamins.
Expression of the Drosophila A-type lamin (lamin C)
lacking a head domain, cause numerous defects in larval
muscles. Muscle cell nuclei are misshapen and exhibit
lamin aggregation, disorganization of the NPC, Otefin,
SUN domain protein and the actin-tubulin cytoskeletal
network [65, 66]. Interestingly, also in other model
organism, Caenorhabditis elegans, EDMD mutation cause
perturbed body muscle ultrastructure and reduced muscle
function, and at the molecular level altered expression of a
number of muscle-specific genes [148]. The DK46 C.
elegans lamin mutant animals showed motility defects and
muscle structure abnormalities, and revealed alterations in
the lamin filament structure at the molecular level [16]. In
the zebrafish model, lack of lamin A or expression of
progerin affected embryogenesis, increased embryo
senescence and aberrant muscle development [116].
The unique feature of laminopathies is that the diseased
phenotype appears in humans much later, typically after
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maturation, than in any other animal model systems studied
so far where abnormal phenotype can be detected at the
embryonic development stage (fly, zebrafish, frogs) or soon
after birth (mice). The disease phenotype in all model
system is easily detectable during postnatal development.
However, the longer the lifespan the longer is the period of
phenotype development. There may be several plausable
explanations for this phenomenon.
Laminopathies affect mostly tissues of mesodermal
origin—mostly striated muscles. Embryonic development
of muscle progenitor cells is governed by morphogens
and is less sensitive for other factors. Lamin A/C, emerin,
MAN1 and other NL proteins are expressed late in the
development when most of muscle progenitor cells were
already formed as dermomyotome or myotome. So in
laminopathies of muscular dystrophy background, muta-
ted proteins can affect only late stages of prenatal
development and postnatal stages of development and
regeneration. The relatively short lifecycle of fruit fly,
C. elegans, zebrafish, frog or even mouse determines their
short prenatal and postnatal development—much shorter
than in humans. So the disease phenotype appears earlier
than in humans.
During late prenatal and postnatal development, mus-
cles increase in size which is correlated with both the
increase in size of particular myofiber, but also with the
increase in amount of myofibers. This process involves
both proliferation of muscle progenitor cells, their main-
tenance, differentiation of resulted myoblasts, fusion and
remodeling of the inter-myofiber connection. During the
maturation period, myofibers reach their final, relatively
fixed size and extracellular connections. Thereafter,
without damage or disease they remain relatively stable
with only minimal turnover of original myonuclei. It
should be pointed out that most muscular dystrophies in
mice models or in humans, although may have different
genetic background, have similar phenotypes and timing
of its appearance. Thus there is a possibility that the
interaction of particular myofiber with surrounding extra-
cellular matrix and neighbouring cells may be affected by
the sarcolemma properties, which changes during growth
as well [89].
In the following chapters, we attempt to demonstrate the
mechanisms and signaling pathways that can affect muscle
development during prenatal and postnatal development
and regeneration. In addition, we analyze both typical
muscular dystrophy laminopathies and HGPS progeria
because many of the mechanisms of disease phenotypes
discovered during studies on Progeria HGPS development
are similar in terms of the involved proteins and pathways.
Especially, those involving epigenetic regulation of gene
expression by mutated lamins and lamina-associated
proteins.
Prenatal myogenesis and its regulatory mechanisms
Skeletal muscles of the trunk and limbs derive from
somites—segments of paraxial mesoderm that form pro-
gressively along the anterior-posterior axis of the neural
tube and notochord. Somitogenesis involves expression of
genes involved in Notch and Wnt pathways, morphogen
gradients of FGF, retinoid acid and Wnt [19].
Dorsal epithelial compartments of the somites give rise
to the structure called the dermomyotome which is divided
into epaxial and hypaxial domains. Dermomyotome cells
show high, but not uniform, level of Pax3 and Pax7 and
low level of Myf5. The lips of dermomyotome develop into
myotome, the primitive muscle structure with committed
muscle cells with high level of MyoD and Myf5. The
central part of dermomyotome dissipates and muscle pro-
genitor cells integrate into the myotome [225, 226]. This
population of cells gives rise to majority of satellite cells in
postnatal muscles.
Pax3- and Pax7-expressing cells within the central
dermomyotome give rise to both the muscle satellite cells
and the embryonic muscle progenitors, which begin dif-
ferentiation after activation of the myogenic determination
genes—Myf5 and MyoD [88]. However, experiments with
Pax7 null mice reveal that Pax7 is not necessary for
muscle differentiation since prenatal development of
knockout mice is normal with the exception of satellite
cells which are progressively lost [201, 202]. This indi-
cates that Pax7 is essential for the maintenance of proper
number of satellite cells in muscles by symmetric divi-
sions of muscle stem cells mediated by planar cell
polarity (PCP) pathway which probably involves Wnt7a,
Vangl-2 and BCL9 [126].
Hypaxial muscles of the body wall originate from
ventrally elongated dermomyotome and myotome [51].
Dorsal muscles are generated by epaxial part of the
dermomyotome and myotome [186]. Limb muscles and
lateral trunk muscles originate from hypaxial domain of
dermomyotome.
The diaphragm, hypoglossal chord and muscles of
extremities originate from ventrolateral lip of dermomyo-
tome at the limb level. Head muscles originate from cells
of prechordal and pharyngeal head mesoderm [201]
(Fig. 1).
Myogenesis is a complex, highly regulated process
based on morphogen gradient patterns, genetic network of
transcription factors and controlled expression of myogenic
regulatory factors. Surprisingly, most of the processes
governing the embryonic development of muscles are
similar to those regulating postnatal growth and regenera-
tion of muscles.
The morphogenetic events that are involved in the for-
mation of the myotome depends on four main pathways—
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Bmp, Shh, Wnt and Notch [135] (Fig. 1). Paracrine factors
involved in these signaling pathways are delivered by tis-
sues surrounding the differentiating somites such as the
neural tube, notochord, surface ectoderm and lateral
mesoderm. They supervise the activation or inhibition of
different myogenic transcription factors such as Pax3 and
Pax7, members of the paired box transcription factors
characterized by the presence of a 128-amino acid paired
domain that enables sequence-specific binding to DNA
[47], which act as upstream activators for myogenic reg-
ulatory factors (MRFs) genes transcription. MFRs belong
to the family of proteins containing a structural motif basic
helix-loop-helix (bHLH) including myogenic factor 5
(Myf5), myogenic determination factor (MyoD), both
expressed mainly during early stages of muscle cell dif-
ferentiation, myogenin and myogenic regulator factor 4
(Mrf4), also known as Myf6 [36]. After fusion, when
mononucleated myoblasts become multinucleated myotu-
bes, other muscle-specific proteins such as myosin heavy
chains are synthesized.
The most important in formation of dermomyotome and
myotome are Wnt proteins. Wnts are conserved lipid-
modified signaling proteins involved in many activities
during embryogenesis and self-renewal in adult tissues
[52]. One of the pathways controlled by Wnts result in the
alteration in b-catenin concentration in the nucleus. In the
presence of Wnts, b-catenin is bound by the complex
which contains, besides Wnts, also frizzled/lipoprotein
receptor-related proteins. Due to this complex, b-catenin
reaches the nucleus, where it binds to T cell factor (TCF)/
lymphoid enhancer factor (LEF) and induces target gene
expression. The inner nuclear membrane protein emerin
plays a crucial role in regulation of the Wnt-b-catenin
pathway, which is responsible for maintenance of stem cell
Fig. 1 A simplified scheme of signaling pathways and cellular events
involved in embryonic skeletal muscle formation. Paraxial mesoderm
which forms somites is distributed bilaterally along the neural tube
(NT) and notochord (NC) at the antero-posterior axis. The ventral
region of the somite forms the sclerotome (S) (which becomes most of
the axial skeleton: vertebrae, ribs), the dorsal part of the somite is
called the dermomyotome (DM). Cellular migration from the
dermomyotome gives rise to the epaxial myotome (EDM; the muscle
of the back) [2] and the hypaxial myotome (HDM; body-wall
muscles, limb muscles, the diaphragm and the tongue) [3]. The
hypaxial dermomyotome is specified by signals from the dorsal
ectoderm (DE) (Wnt pathway: Wnt7a) and the lateral plate mesoderm
(Bmp4) [7]; Wnt7a activates, while Bmp4 inhibits the expression of
MyoD. The neural tube (NT) and notochord (NC) provide signals
necessary for epaxial myogenic determination: Wnt1/3a, produced by
dorsal NT [8], acts together with Sonic hedgehog (Shh) produced by
NC [6]. The epaxial myotome can be identified by Myf5 expression,
while the cells of the hypaxial myotome predominantly express
MyoD. Muscle progenitor cells delaminate from the dermomyotome
(DM) and migrate laterally to form the myotome [1] as well as
migrate into the limb bud [5], where they continue to proliferate and
differentiate later. In limb muscle formation, Shh is also necessary
[9]. A anterior, P posterior, D dorsal, V ventral, M myotome Bmp4
inhibition of the MyoD expression is accompanied by Notch signaling
[10] which is responsible for the prevention of early myogenic
differentiation of limb buds progenitor cells [11]
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and fate differentiation [231]. Interactions with b-catenin
are mediated by a conservative APC-like domain located at
the C-terminal end of emerin [146]. However, recent
investigations suggest the existence of direct interaction
between b-catenin and MyoD with the omission of
LEF/TCF [110]. Constitutive expression of endogenous
b-catenin or inhibition of its degradation leads to an
increase in the subpopulation of Pax7-positive satellite cells
and a decrease in the level of cells undergoing terminal
differentiation. Reduction of the b-catenin level increases
myogenic differentiation of muscle progenitors [188].
Wnt proteins act through canonical b-catenin/TCF
dependent pathway and non-canonical pathway through
PKC. Wnt1/3 are secreted from dorsal neural tube while
Wnt4/6/7a are secreted from surface ectoderm. Wnt1/3
induces Myf5 expression and stimulates Pax3 expression
while Wnt4/6/7a stimulates expression of MyoD. Receptor
for Wnt7 Frizzled7 (Fzd7) is expressed in hypaxial part of
the somite while Fzd1 and Fzd6 (receptors for Wnt1/6) are
expressed in epaxial domain. Wnt1 in epaxial domain
acts through canonical pathway which leads to expression
of Myf5 while Wnt7 (Fzd7) signaling induces MyoD
expression through PKC pathway [34]. Thus the differen-
tiation of muscle progenitor cells in hypaxial domain and
epaxial domain is regulated diifferently, via different
muscle-specific transcription factors.
Another important morphogen—Sonic hedgehog (Shh) is
released from notochord and floor plate of neural tube.
Together with two other members of the Hedgehog family:
Indian hedgehog (Ihh) and Desert hedgehog (Dhh), Shh
interacts in mammals with Patched receptor releasing
smoothened (the G protein-coupled receptor protein), which
in turn regulates target genes transcription through GLI
transcription factors [138]. Proper Shh signaling seems to be
necessary for maturation of dermomyotomal cells into
MyoD/Myf5 positive, committed cells with down regulated
Pax3/Pax7 since lack of Shh signaling in myotome results in
reduced expression of Myf5 and increases the number of cells
with high level of expression of Pax3 and Pax7 which in turn
results in blocking of the progression of differentiation.
Shh signaling and canonical signaling through Wnt
simultaneously activate the expression of Myf5 gene due to
the presence of regulatory elements in Myf5 promoter
which are recognized by TCF and GLI transcription factors
[24]. It should be pointed out that GLI transcription factors
can be inhibited by several kinases such as GSK3b, PKA
and CK1 which has its further implication also for post-
natal muscle cells regulation and shows the complicity of
signaling and feedback signaling pathways during muscle
development and regeneration.
Interestingly, the abnormally high level of Shh results in
induction of sclerotomal marker Pax1 and reprogramming
cells into different developmental pathway.
Another important morphogen—bone morphogenic
protein (BMP) modify the expression of myogenic genes.
BMPs as a subclass of TGFb proteins signal through
serine/threonine kinase receptors and activate transcrip-
tion through Smad proteins. BMP2/4/7 activates Smad1/5/
8 which after complex formation with Smad4 translocates
into nucleus and interacts with CBP/p300 and specific
transcription factors (e.g. AP-1, bZIP, RUNX, Fox,
bHLH). TGFb and activins act similarly but through
Smad2/3 proteins [160]. It is essential to know that BMP
signaling and TGFb signaling also triggers some mitogen
activated protein kinase pathways (MAPK) including
activation of p38, JNK, ERK1/2 and other intracellular
signaling components such as PKC, mTOR and cofilin
[58] (Fig. 3d).
In dermomyotome BMP4 increases the level of
expression of Pax3 and delays the expression of Myf5 and
MyoD which results in expansion of muscle progenitor
cells.
Notch signaling is also essential in myogenesis [214].
Notch, a single-pass transmembrane receptor with a large
extracellular and a small intracellular domain (NIC), during
somitogenesis is involved in the determination of somite
borders and polarity along the anterior-posterior axis [130].
Notch signaling is based on the interaction of protein Delta/
Jagged exposed on surface of ‘‘presenting’’ cell with Notch
exposed on surface of ‘‘target’’ cell. Delta1 protein is
presented to embryonic muscle progenitor cells by
migrating neural crest cells. Notch ligands (DLL1-3, Jag1-
2) produced by neighboring cells activate Notch and induce
the cleavage off of the NIC domain of Notch. This domain
migrates to the nucleus, assembles with CSL factor (CBF1/
SuH/Lag-1) and Mastermind (Mam) and activates expres-
sion of target genes (Hes family, Myc,p21, Cyclin D3).
This in turn alters the expression of different genes [73].
Active Notch suppresses MyoD expression by stimulation
of expression of transcription repression protein Hes1.
Thus Notch signaling promotes myogenic precursors
expansion. Augmentation of BMP signaling results in
increase of the number of fetal muscle progenitors and
satellite cells in contrast to its repression which has
opposite effects [97]. Some reports suggest that the Notch
repressive effect on muscle differentiation arises from the
ability of the NIC to prevent binding between Maml and its
co-activator Mef2 [251] (Fig. 3c). It is worthy to note that
the NIC induces expression of MKP1 phosphatase that
inhibits p38 kinase involved in the MAP signaling pathway
[114].
In order to properly develop the limb muscles, which
develop distantly from somites, Pax3-dependent migrating
progenitors are required. In mice, depletion of Pax3 causes
defects in myogenic progenitor migration, which in turn
leads to the suppression of limb muscle development [159].
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Limb muscles development starts at the level of limbs in
ventral dermomyotome which undergo epithelial to mes-
enchymal transition (EMT). Long-distance migrating
muscle progenitor cells are directed by several factors such
as N-cadherin, fibronectin, hepatocyte growth factor (HGF)
and its receptor c-Met [36].
In myogenesis, the key role play myogenic regulatory
factors: Myf5, MyoD, myogenin and MRF4 (Myf6). Myf5
is the first myogenic factor expressed transiently during
embryonic development in paraxial mesoderm and later on
during the formation of myotome together with MyoD.
Myf5 and MyoD may compensate for themselves to certain
degree during development but nevertheless at least two
populations of muscle progenitor cells are present in
myotome: Myf5 positive and MyoD-positive. Both Myf5
and MyoD induce expression of myogenin and MRF4 for
myoblast terminal differentiation [77].
Another key role in the regulation of myogenesis play
Paired-Homeobox transcription factors: Pax3 and Pax7.
Cells in dermomyotome express Pax3 and Pax7. Highest
level of Pax3 is in the dorsal and ventral lips while Pax7
is overexpressed in the central domain of dermomyotome.
However, Pax3 is expressed in long-distance migrating
cells which form initial limb musculature [202]. In mice,
depletion of Pax3 causes defects in myogenic progenitor
migration, which in turn leads to the suppression of limb
and diaphragm muscle development [159]. Current data
on Pax3:Pax7 double knockout mutants indicate that Pax3
positive cells are the founder cells (FC) forming initial
fibers of muscles in the limb to which secondary fibers
and satellite cell pool is added by Pax7 positive cells.
Pax3 expression, as well as MyoD, MRF4 and myogenin,
is under control of Six1 (sine oculis-related homeobox 1)
and Six4 transcription factors. Pax3 and Six proteins
participate together in the activation of Myf5 protein
promoter.
There is also a feedback mechanism regulating myo-
genesis involving several microRNAs. The miR206 is
upregulated by MyoD targets and inhibits translation and/
or degrades mRNAs for Pax3 and Pax7 which facilitates
the progression of differentiation.
Proper muscle development requires myoblast fusion.
During this process, mononucleated myoblasts become
multinucleated myotubes [96]. General rules underlying
myoblast fusion are similar in many organisms: FC fuses
with the neighboring fusion-competent myoblasts (FCMs).
This process is regulated by the asymmetrical distribution
of molecules in both the FC and the FCMs [67]. However,
it needs to be mentioned that not all invertebrate and ver-
tebrate muscle cells undergo fusion that leads to syncytium
formation.
The course of myogenesis is strictly connected with the
activity of proteins controlling the cell cycle. For instance,
transcriptional activity of Pax3 and Pax7 is modulated due
to the interactions with many cofactors, among which
members of the retinoblastoma (Rb) family that control the
cell cycle exit through modulation of the E2F factors, has
to be mentioned [245]. The Rb protein is regulated by
cyclin-dependent phosphorylation which comprises the
involvement of cell cycle proteins such as cyclin-depen-
dent kinase inhibitor—p21, and cyclin D3 [178].
Hyperphosphorylation contributes to Rb inactivation in
proliferating myoblasts. Differentiation signals cause Rb
dephosphorylation, which promotes its interaction with
E2F transcription factors preventing cell cycle progression
and involvement in the synthesis of late skeletal muscle
differentiation markers—muscle creatine kinase and Mrf4
[61, 62] (Fig. 3l). Inactivation of the E2F transcription
factors occurs by its binding to dephosphorylated Rb pro-
tein in complex with LAP2a and lamin A. Due to the
interaction, the cell remains stalled in the G1 phase. Rb is
also engaged in myoblast fusion, muscle fiber formation
and the maintenance of terminally differentiated muscles
[104].
Myogenesis is also regulated by associations between
bHLH factors and Mef2. The activity of these factors is
regulated by their interactions with histone deacetylase
(HDAC), histone acetyltransferases, and the SWI/SNF
chromatin remodeling complexes [151]. During differen-
tiation, muscle-specific genes are activated by the release
of HDAC from their promoters. For example, dephospho-
rylated Rb is able to bind HDAC, which allows it to take
part in MyoD acetylation (by CBP–CREB-binding protein)
by releasing it from HDAC1. This process is modulated by
phosphorylation and recruitment of histone acetyltransfer-
ase (e.g. myogenin is switched on by the release of HDAC
from its promoter through phosphorylation and recruitment
of histone acetyltransferase via MyoD and Mef2) [151].
MyoD, together with MEF2, induces expression of the
genes responsible for cell cycle withdrawal and terminal
differentiation [104] (Fig. 3k).
The enzymes mentioned above, which modify chromatin,
participate in the regulation of myogenesis, due to the for-
mation of complexes with transcription factors that
recognize a specific DNA sequence located at gene regula-
tory regions. These complexes influence gene expression via
control of the spatial organization of the chromatin [210].
Due to many studies, it is currently known that proper
muscle development also requires engagement of the NE
proteins (A-type lamins, emerin, LAP2a, MAN1) which
form a functional scaffold for different transcription factors
and create complexes that modulate activity of muscle
differentiation factors e.g. myogenin and cell cycle con-
trolling proteins such as Rb [15, 72, 145].
Overexpression of mutant lamin A (R453) causing AD-
EDMD disrupts differentiation of C2C12 myoblasts
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correlates with decrease in the expression of myogenin and
with accumulation of hyperphosphorylated Rb protein.
These abnormalities lead to deficiencies in interactions
necessary for cell cycle arrest and myoblast fusion neces-
sary for the formation of mature myotubes [72]. Also the
NE proteins’ expression and distribution is changed in the
presence of the other AD-EDMD-causing lamin A mutant
(W520S). During normal myoblast differentiation, the
following changes are observed: increase in lamin B2
expression, decrease in LAP2a expression, reduction of
lamin A and C solubility and their redistribution. The
presence of mutant lamin A which accumulates in the
nucleoplasm results in inhibition of myoblast differentia-
tion caused by disruption of underphosphorylated Rb/
LAP2a complexes [145], which are formed under normal
conditions when Rb dephosphorylation is necessary for the
onset of differentiation (Fig. 3k). Also reduction of lamin
A or emerin levels is correlated with the decrease in
expression of four important differentiation factors: MyoD,
desmin, Rb and M-cadherin. Moreover, because in lamin A
knockout myoblasts expression of Pax7 and Pax3 is not
disrupted [75], it seems that impaired differentiation results
directly from a lamin A deficiency.
Postnatal myogenesis and its regulatory mechanisms
Postnatal muscle growth is associated with the activation
and differentiation of embryonically derived myoblasts
present in the satellite cell pool [179]. The presence of
Pax7 ? cells which can contribute to muscle growth and
regeneration in juvenile and adults was recently confirmed
in various species [46]. The role of Pax7 in postnatal
myogenesis seems to be consistent with the regulation of
Myf5 expression in myoblasts derived from satellite cells
by binding to a paired domain motif-containing enhancer
[37]. However, recently obtained results about Pax7
activity are equivocal and inconsistent. For example, on the
one hand Pax7 stimulates myogenesis via up regulation of
Myf5 in a histone methyltransferase complex dependent
manner, but on the other hand Pax7 contributes to the
suppression of myogenesis by MyoD inhibition [149].
A growing number of studies indicate that activities of
different myogenic regulatory factors are developmental
stage-dependent and may be substituted by various pro-
teins (among which not all have been identified) that
mediate reciprocally connected or completely independent
signaling pathways. For example, Pax7-depleted muscles
derived from juvenile and adult individuals differ in
phenotypes. This is due to Pax7 involvement in myo-
genesis during the juvenile period when progenitor cells
make the transition into quiescence [128]. Furthermore,
although depletion of Pax7 is not substituted by Pax3
activity, compensation for its loss by other related pro-
teins in the adult, but not in the embryo or the pups,
cannot be excluded [239]. Involvement of bHLH factors
in postnatal myogenesis was also investigated. For
example, postnatal (contrary to prenatal) inactivation of
myogenin does not have dramatic effects on muscle
activity except for body size, which is reduced [112]. This
suggests its minor role in the maintenance of adult muscle
homeostasis.
Adult myogenesis with reference to muscle regeneration
via satellite cell activity is discussed in the next section.
Regulation of prenatal satellite cells development,
maintenance and adult muscle regeneration
Satellite cells originate from a population of undifferenti-
ated stem cells in the embryonic dermomyotome [88]. All
satellite cells in limb muscle originate from Pax3 ? cells
of the hypaxial dermomyotome [213]. The presence of
Pax3 is necessary for mesenchymal epithelial transition
factor (c-Met)—tyrosine kinase receptor expression which
is engaged in delamination and enables proliferation of
muscle precursors as well as their migration from dermo-
myotome into the limbs [22]. Pax3 modulates expression of
c-Met via the interactions with regulatory sequence in the
c-Met promoter [38].
Pax7 is one of the characteristic markers of satellite
cells. Its presence was observed within two subpopulations
of adult muscle stem cells: Myf5-/Pax7? (true muscle stem
cells) and Myf5?/Pax7? (committed progenitors) [117].
Both types of cells are generated during asymmetric divi-
sion. Former group is responsible for self-renewal of the
satellite cell population, latter takes part in terminal dif-
ferentiation program leading to formation of new muscle
fibers [117]. Muscle progenitor cells express other genetic
markers: M-cadherin—a cell surface adhesion protein that
probably plays role in terminal muscle differentiation,
CD34—surface marker of quiescent satellite cells [254]
and myostatin—secreted member of TGFb family that
ensures the resting state of satellite cells.
At the end of fetal life, myogenic progenitors known as
satellite cells relocate at muscle fibers. These mononucle-
ated, quiescent stem cells are embedded within the basal
lamina and during postnatal growth or in case of injury or
pathological conditions (e.g. dystrophies) they are acti-
vated, start to differentiate and fuse to form new muscle
fibers.
Satellite cells are capable of self-renewal due to their
capacity for asymmetric division, which gives rise to two
nonidentical daughter cells. One of these cells remains
quiescent while the other is activated and undergoes
myogenic differentiation. Asymmetric division is
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accompanied by asymmetric segregation of Numb protein
(Notch inhibitor), which is inherited by the daughter cell
that becomes an FC and takes part in muscle formation,
whereas the second sibling cell suspends its differentiation
process [117]. The subpopulation of satellite cells, which
after proliferation downregulates Pax7, differentiates,
whereas cells which maintain Pax7 expression and inhibit
production of MyoD return to a quiescent state [117]
(Fig. 2). Recent studies indicate that the persistent contact
with the basal lamina of the myofiber allows satellite cells
to retain their stem cell status. Loss of contact leads to the
activation of a differentiation program which is preceded
by Myf5 expression. Moreover, active Bmp signaling
occurs in proliferating satellite cells during regeneration,
which suggests that this pathway is crucial for activated
satellite cells in adults [240].
Since the presence of Pax7 is essential in myogenesis and
satellite cells maintenance, specification, self-renewal and
expansion (also in adulthood) [181] downregulation of Pax7
by myogenin promotes myogenic differentiation. Similar to
Pax7, which is expressed by all satellite cells and acts as a
survival factor, Pax3 is found in adult satellite cells. How-
ever, its presence is restricted to cells from the diaphragm
and a subset of lineages of forelimb muscles [117].
Interactions between the Wnt and Notch signaling
pathways play a crucial role in the maintenance and acti-
vation of muscle satellite cells through canonical pathway
[28] (Fig. 3a, c). b-catenin, located in a multiprotein
complex at the plasma membrane, is also engaged in
myoblast fusion by binding with cell adhesion complexes
containing cadherins [78].
In adult satellite cells, the activity of the Notch signaling
pathway prevents their premature differentiation. Muscle
injury contributes to Notch activation [55]. This leads to
enhanced proliferation and satellite cell expansion. Sub-
sequent inhibition of Notch signaling precedes activation
of the canonical Wnt signaling pathway that plays a role in
late stages of muscle regeneration during which differen-
tiation into myoblasts of previously multiplied cells must
occur [28]. However, it should be noted that some
researchers obtained inconsistent data according to which
the activation of b-catenin-dependent Wnt signaling is
associated with the activation of satellite cell self-renewal
[188].
The Notch pathway links with Wnts signaling via
intracellular signaling glycogen synthase kinase 3b
GSK3b. Canonical Wnt signaling in contrast to the Notch
pathway inhibits kinase GSK3b activity [126].
One of the NE protein, emerin, is also engaged in reg-
ulation of the Wnt-b-catenin pathway due to the
interactions with b-catenin which are mediated by a con-
servative APC-like domain located at the C-terminal end of
emerin [146].
The non-canonical Wnt pathway is also engaged in
regulation of satellite cell self-renewal. During muscle
regeneration, Wnt7a together with its receptor Frizzled7
(Fzd7) through the mediation of the planar cell polarity
pathway stimulates the symmetric expansion of the satellite
cell pool [126].
Inappropriate Wnt signaling disrupts muscle regenera-
tion, leading to disease [28]. It is particularly interesting in
the light of recent reports that in aged muscles a high level
of Wnt signaling in quiescent and early activated satellite
cells contributes to activation of the fibrogenic or adipo-
genic program [55]. Disruption of these signaling pathways
by EDMD-causing mutations could also lead to
Fig. 2 Regulation of proliferation and differentiation of myogenic
progenitor cells. The diagram demonstrates the stages of myogenic
progenitor cell transformation into quiescent satellite cells and upon
activation/injury into activated satellite cells. Activated satellite cells
expressing MyoD and Pax7 undergo proliferation stimulated by
hyperphosphorylated Rb protein and cyclin D1. Proliferated satellite
cells undergo cell cycle arrest correlated with the loss of Pax7
expression. Further differentiation into myoblasts is induced by pRb,
myogenin, MRF4, MEF2 and p21. After alignment, myoblasts
undergo fusion into myotubes. See main text for detailed description
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misregulation of muscle repair and thus to the development
of dystrophic phenotypes [212].
In muscles of patients suffering from different muscular
dystrophies the regenerative potential is lower than that in
the healthy tissues [55, 136, 162]. Satellite cells do not
contribute properly towards the regeneration of diseased
muscles [1, 207]. Abnormalities of satellite cells may be
induced by mutations in genes coding for lamin A and
emerin which leads to the weakness of adult myofiber
regeneration, causing e.g. EDMD progression [145, 188].
This has been observed in satellite cells from patients
with AD-EDMD or LGMD1B. In the diseased adult muscle
progenitors, disorganization of chromatin was accompa-
nied by increased numbers of Pax7-positive nuclei and a
reduced number of MyoD-positive nuclei [185]. These
results are in perfect agreement with previous observations
indicating that reciprocal inhibition between the tran-
scription factors Pax7, MyoD and myogenin modulates
satellite cell fate decisions probably through typical cell
cycle regulation mechanism associated with lamin A,
LAP2a and pRb complexes [83, 84, 174].
Mice lacking emerin also exhibit defects in muscle
regeneration connected with abnormalities in the cell cycle
[155]. Observed changes are associated with the distur-
bances of transcriptional pathways dependent on Rb
protein and MyoD. Compared to normal myogenic cells,
Emd null myoblasts showed prolonged hyperphosphoryla-
tion of Rb [15].
It is noteworthy that other types of adult muscle stem
cells (mesenchymal stem cells) are affected by abnormal-
ities in the Notch and Wnt signaling pathways caused by
mutations in genes coding for A-type lamins [212] or
ZMPSTE24 [70]. These disorders lead to a laminopathy
called Hutchinson–Gilford progeria syndrome (HGPS) [69,
237] or a more severe restrictive dermopathy (RD) [175],
rare childhood diseases characterized by premature ageing,
alopecia, wrinkled skin, loss of subcutaneous fat, joint
abnormalities and early death (in the neonatal/perinatal
period in the case of RD) [69, 70, 163, 212, 237].
Side population (SP) cells—another muscle stem cell
population
Muscle regeneration is mainly conjoined with the satellite
cells. However, some studies assume that another stem cell
fraction known as side population cells (SP cells) which are
present in skeletal muscles (termed skeletal muscle SP
cells) are involved in this process [90, 91]. Although
experiments undertaken within recent years has generated
valuable data about SP cells localization, embryonic ori-
gins and activity, their exact role in muscle regeneration
remains elusive.
Side population cells are a group of hematopoietic stem
cells belonging to bone marrow stem cells (BMSCs) and
are localized in the interstitial connective tissue of the
skeletal muscle close to the blood vessels. They were first
identified due to their ability to exclude Hoechst 33342 dye
[82].
The SP cells can be considered as a potential tool in
medical treatment of muscle diseases due to their qualities
that are considered indispensable for muscle regeneration.
When injected into muscle of lethally irradiated mice, SP
cells, besides causing recovery of the hematopoietic sys-
tem, are able to differentiate into myoblasts [91].
Moreover, it was also reported that SP cells delivered to
injured muscles contribute to their recovery by undergoing
differentiation into satellite cells and can take up a position
in their niche [150]. SP cells may be of great interest to
scientists elaborating therapeutic strategies for dystrophic
patients due to their ability to be delivered systemically
through the circulation, which may facilitate repair of
diseased muscles [13].
The majority of limb muscle SP cells, similar to limb
muscle satellite cells, originate from cells expressing Pax3
and their migratory derivatives located in the hypaxial
somite. SP cells with somitic origins display greater
myogenic potential than SP cells which are derived from
other regions [213]. Non-somitic sources from which a
small fraction of SP cells may arise are bone marrow,
hematopoietic stem cells, and endothelial cells. This
diverse provenance is reflected in SP cell marker hetero-
geneity [213].
The SP cells are a heterogeneous population among
which CD45? and CD45- fractions can be distinguished.
These two groups indicate myogenic potential but only SP
CD45? includes cells with hematopoietic potential [11].
Due to the identification of the novel marker CD31, further
characterization of SP cells was made possible [234]. This
allowed the subdivision of the known pool of SP cells
which appeared to be more heterogeneous with respect to
their differentiation potential. CD31?/CD45- SP cells are
the main sub-fraction in non-regenerating muscle, whereas
not so numerous CD31-/CD45- SP cells reveal greater
myogenic potential in vitro as well as in vivo. Furthermore,
in case of an injury they become the prevailing fraction and
express regulatory genes which are crucial during muscle
regeneration as well as muscle markers [234].
Skeletal muscle SP cells are distinct from bone marrow
side population cells and satellite cells and exhibit a spe-
cific marker, stem cell antigen-1 (Sca-1), which is not
present on adult satellite cells [161]. It has been shown that
in Pax7 null mice the fraction of satellite but not the side
population cells was reduced [215]. This suggests that SP
cells, in contrast to satellite cells, arise independently of
Pax7.
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SP cells reveal their myogenic potential (inter alia by
Pax7 expression) when they are cultured together with
C2C12 myoblasts [11]. SP cells may also be related to (at
least some subset of) satellite cells, as was demonstrated in
the studies undertaken by Tanaka and co-workers [227]. In
their research, SP cells also expressed, besides Sca-1,
syndecan-4 (a marker of satellite cells) and Pax7. More-
over, newly identified cells reside beneath the basal lamina
in the satellite cell position and were able (after direct
injection) to regenerate diseased muscles. Because of these
features, the term satellite-SP cells has been proposed
[227].
Mutations in laminopathies affect myogenesis, postnatal
muscle growth and muscle regeneration by various
mechanisms
Current data indicate that lamins and lamina-associated
proteins of NE may affect most of the signaling pathways
involved in myogenesis during both embryonic develop-
ment and postnatal muscle growth and regeneration. It
seems that similar signaling pathways govern the muscle
cell specification in dermomyotome and myotome during
embryogenesis as during postnatal muscle growth. Thus,
the major unanswered question is when do lamins and
lamina-associated proteins start to be expressed during
embryogenesis and what interacting protein partners are
also present in particular tissue? The recent discovery that
lamin A/C mRNA can be detected in mice during
embryogenesis at the stage E11 in heart, outflow tracts,
dorsal aorta, liver and somites [119], proves that lamins
and lamina-associated proteins can indeed affect embry-
onic myogenesis [205]. Although, two animal models of
lamin A/C knockout [119, 223] differ in severity of
phenotype, together with many mice laminopathy models,
they provide the same message, that lamins and lamina-
associated proteins affect myogenesis and muscle
regeneration.
Cell cycle control and regulation of Rb
Cell cycle control and regulation of Rb location and
phosphorylation status seems to be the most obvious
mechanism by which lamins and lamina-associated pro-
teins may affect myogenesis and regeneration. The link
between pRb, LAP2a, lamin A and muscles was estab-
lished by detailed analyses of effects caused by loss of
A-type lamin expression and provided the first direct
evidence that the location of lamins within the nucleus is
important for cellular differentiation [72, 145]. Observed
abnormalities are correlated with decrease in the
Fig. 3 The molecular background of major signaling pathways
responsible for proper development of muscles and muscle stem cells
in normal tissues and tissues affected by laminopathy. Only major
signaling pathways are shown. In the case of Wnt and Notch signaling
pathways, only essential fragments of pathways for muscle tissues are
shown. In the case of TGFb-related pathways, only four different
pathways are shown as an example of possible interactions. a Wnt/b-
catenin signaling is activated by ligands of the Frizzled receptor, which
triggers a signaling cascade resulting in the displacement of the
multifunctional kinase GSK3b from the APC/Axin/GSK3b complex.
Free GSK3b is not able to phosphorylate b-catenin. Hypophosphory-
lated b-catenin accumulates in the cytoplasm and is translocated to the
nucleus, where it can be immobilized in nuclear envelope (NE) by
emerin binding (inactive b-catenin) or can translocate to the nucleo-
plasm, where it activates its target genes via TCF/LEF (T cell factor/
lymphoid enhancer factor) transcription factors. Mutations in emerin
could change b-catenin cellular localization and thus influence its
activity. In the absence of Wnt, cytoplasmic b-catenin is constantly
phosphorylated by GSK3b in a protein complex, which leads to
b-catenin ubiquitination and proteasomal degradation. b For proper
myoblast differentiation, LIM-domain only 7 (Lmo7) is needed. This is a
transcription factor that regulates Pax3 expression. Emerin binds to and
inhibits the activity of Lmo7. c Notch binding to ligand elicits several
steps of cleavage; thus the intracellular domain (NICD) of this protein is
released and translocated into the nucleus where it forms a complex with
the DNA-binding CSL transcription factor and the transcriptional co-
activator Maml. This complex induces the expression of Hes1 and Hes5
genes. The Notch repressive effect on muscle differentiation arises from
intracellular domain of Notch (NICD) ability to prevent binding between
MAML and Mef2. d Bmp4 acts by augmentation of Notch-dependent
transcription, inducing phosphorylation of Smads, which after hetero-
dimerization with Smad4 leads to transcription stimulation of target
genes including expression of Hes1 and Hey1 molecules. e, f SREBP1
interacts with pre-lamin A, but not with the mature form of this protein.
SREBP1 is a transcription factor which regulates lipogenesis, and plays
a role in the transactivation of the PPARc promoter (f). Following
activation by retinoic acid, PPARc forms heterodimers with RXR
(retinoid X receptor) and modulates gene transcription. Mutations of
lamin A cause the retention of SREBP1 at the NE and decrease the
SREBP1 level in the nucleoplasm, which reduces the expression of
PPARc and other genes. g, h Lamin A is phosphorylated on the S404
residue by Akt/PKB kinase downstream of the phosphoinositide-3-
kinase (PI3 kinase) signaling pathway. The phosphorylation of lamin A
might modulate interaction with protein partners, impair lamin
polymerization or promote association with the 14.3.3 protein. Lamin
mutations can inhibit S404 phosphorylation and lead to changes in NE
stability. j The MAPK kinases activate extracellular signal-regulated
kinase (ERK) and c-Jun NH[2]-terminal kinase (JNK). Active,
phosphorylated ERK1/2 and JNK kinases are translocated to the nucleus
where they interact with A-type lamins at the nuclear periphery and
phosphorylate c-Fos and c-Jun, causing their release from the NE, thus
allowing the transcriptional activation of responsive genes. Lamin A
mutations, inhibit the binding of mutated lamin A/C proteins with ERK
and JNK kinases, cause their release from the complex with lamins and
in consequence increase the activity. k, l Lamins could modulate TGF-b-
dependent signaling through interaction with protein phosphatase 2A
(PP2A). PP2A dephosphorylates pRb, and dephosphorylated Rb is able
to bind MyoD. The MyoD-Rb-lamin A-LAP2a complex induces the
expression of genes associated with myogenesis. Cdk4 phosphorylates
MyoD, releasing it from the lamina-LAP2a-pRb complex, leading to the
inactivation of myogenesis. This creates an opportunity for pRb to take
part in the regulation of cell cycle progression and proliferation. In the
absence of wild-type lamin A/C, PP2 is unable to dephosphorylate pRb
in the lamin A-LAP2a complex. Phosphorylated pRb does not bind
MyoD, and this leads to inactivation of myogenesis and a decrease in
MyoD and pRb levels. See main text for adetailed description
b
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expression of myogenin and with accumulation of
hyperphosphorylated Rb protein. Moreover, in the pres-
ence of mutant lamin A (R453W), myoblasts are able to
express proliferation markers but they display deficiencies
in interactions necessary for cell cycle arrest and they do
not fuse to form mature myotubes. These data led to the
hypothesis that the transition of myoblasts into myocytes
depends on a functional scaffold built by the lamins and
their partners [72]. During normal differentiation, the
level of lamin B2 increases while LAP2a expression
decreases, lamin A and C proteins are redistributed and
less soluble. In AD-EDMD-causing lamin A mutants (e.g.
W520S) inhibition of myoblast differentiation is observed
by preventing reorganization of NL. The presence of
mutant lamin which accumulates in the nucleoplasm
results in the disruption of underphosphorylated Rb/
LAP2a complexes [145], which are formed in normal
conditions when dephosphorylation of Rb is necessary for
the onset of differentiation. Disruption of mentioned
complexes is correlated with loss of Rb synthesis. More-
over, expression of exogenous lamin A causes retention of
LAP2a in the insoluble complexes within the nucleoplasm
[145] Loss of LAP2a in mice results in delay in satellite
cells differentiation and postnatal fiber differentiation
most probably due to the lack of ability to form nucleo-
plasmic LAP2a-lamin A complexes which play crucial
role in proper timing of reprograming of muscle progen-
itor cells from proliferation to differentiation [83, 84, 174]
(Fig. 3k).
Beside lamin A, emerin also is involved in EDMD
development. Myoblasts with decreased emerin expression
show changes in differentiation phenotype similar to those
observed in LMNA knockout mice. In both cases, reduced
level of lamin A or emerin is correlated with decrease in
the expression of four important differentiation factors:
MyoD, desmin, Rb and M-cadherin. Reduction of cyto-
plasmic protein, desmin and MyoD as a result of lamin A
knockout shows their importance in muscle formation,
because restoration of their normal level increases the
differentiation potential in lamin A null myoblasts. More-
over, these findings suggest that reduction of desmin,
which acts as a mediator between the cytoplasm and the
nucleus, could contribute to deficiency in communication
between these two compartments [75].
The Rb protein, which is regulated by cyclin-dependent
phosphorylation, seems to play a crucial role both in pro-
liferation of activated myoblasts and in the cell cycle exit.
Hyperphosphorylation, specifically pocket C phosphoryla-
tion, contributes to Rb inactivation in proliferating
myoblasts. Differentiation signals cause Rb dephospho-
rylation, which promotes its interaction with E2F
transcription factors preventing cell cycle progression [61]
(Fig. 3l).
One explanation of the pathological mechanism leading
to the development of dystrophic phenotypes assumes that
mutations in genes coding for the NE components trigger
destabilization of the transcriptome in differentiated cells.
The transition from myoblast proliferation to cell cycle exit
is correlated with differences in expression of important
lamina components: lamin B1, LAP1 and LBR levels
decline, whereas those of lamin A/C, lamin B2 and LAP2
increase [15]. Disruption of interactions between the NE
elements lamin A and emerin, Rb protein and MyoD cause
failure of critical steps during myoblast exit from the cell
cycle. Abnormalities are induced by incorrect timing of
phosphorylation and acetylation of these proteins [155]. As
mentioned above, hypophosphorylated Rb takes part in
acetylation of MyoD (by CBP–CREB-binding protein) by
releasing it from HDAC1 [197]. MyoD, together with
MEF2, induces genes responsible for cell cycle withdrawal
and terminal differentiation [104] (Fig. 3k). Loss of lamin
A and emerin may disrupt muscle function and regenera-
tion differently. LMNA null mice and myoblasts, differ
from EMD null mice and myoblasts and pathways involved
in muscle regeneration are affected differently [14, 155].
Recent studies have allowed the molecular basics of
symptoms typical for EDMD to be explained. The other
phenotypes (including lipodystrophy and cardiomyopathy)
associated with different mutations in the LMNA gene
might also be caused (at least partly) by alterations in the
cell cycle timing and differentiation. These two processes
are critical for the development of various tissues, includ-
ing muscle, heart and adipocyte, and remain under strict
control of the pocket proteins family: Rb, and Rb-like
proteins RBL-1 (p107) and RBL-2 (p130) [115]. Regula-
tion of the development of different tissues may require
interaction between Rb/lamin A/LAP2a complexes and
various tissue-specific transcription factors. This is con-
sistent with the discovery of another lamin A binding
partner, sterol regulatory element binding protein
(SREBP), a transcription factor important for adipogenesis
[15, 134] (Fig. 3e, f). The abnormal mechanisms of cell
cycle regulation associated with laminopathies involving
abnormal signal transduction are discussed below.
The involvement of lamins and lamina-associated
proteins in signal transduction
Nuclear envelope and nuclear lamina proteins including
A-type lamins are engaged in modulation of the MAPK,
Wnt-b-catenin, TGFb/Smads, Akt, mTOR, Shh and Notch
signal transduction pathways. Misregulation of these signal
cascades is often observed in several laminopathies and
may lead to an explanation of their pathogenesis and
etiology.
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MAPKs
Among signaling pathways controlling cell proliferation,
growth and differentiation that influence muscle formation,
the MAPK-ERK1/2 cascade should be mentioned (Fig. 3j).
Activation of MAPK signaling kinases induces a kinase
cascade, including ERK5, p38, JNKs and ERK1/2/1c,
which phosphorylates target effectors (cytoplasmic or
nuclear) and transcription factors [191, 192]. In satellite
cells, inhibition of p38 disrupts both the activation of
quiescent satellite cells and terminal differentiation [107].
This is consistent with the fact that activation of some
target genes of MyoD depends on p38 kinase activity.
A-type lamins are a binding partner for the transcrip-
tion factor c-Fos, which together with c-Jun participates in
formation of AP1—the transcription factor activating
protein mediating cell proliferation and differentiation
[80]. Please note that c-Fos is a target of three signal
cascades: ERK5, p38 and ERK1/2/1c while c-Jun is
activated by p38 cascade so these proteins are important
participants in all signaling pathways that belongs to the
MAP kinase family. Lamins sequester c-Fos to the NE.
This allows cells to remain in a quiescent state. The
activation of ERK1/2 causes c-Fos release and turns on
the transcription of target genes necessary for cell
spreading [80]. This is consistent with the fact that lamin
A null cells exhibit increased proliferation [105]. Fur-
thermore, similar observations have been made for Rb
protein. In this case, cell proliferation was also enhanced
by lamin A depletion [187].
For proper muscle differentiation, inactivation of ERK1/
2 must occur. Patients with EDMD2 exhibit increased
activation of ERK1/2. Analysis of gene expression profiles
from mouse models of EDMD (H222P and emerin-null)
revealed abnormalities in the MAPK pathway, which is
involved in the development of cardiomyopathy. More-
over, hyperactivated ERK1/2 has been observed in LMNA
knockout HeLa cells, C2C12 myoblasts and AD-EDMD
model mice [167, 170].
TGFb/BMP
TGFb/BMP/Activin signaling pathways act through
Smad1/5/8 proteins or through Smad2/3 proteins. BMP
signaling and TGFb signaling also triggers some mitogen
activated protein kinase pathways (MAPK) including
activation of p38, JNK, ERK1/2 and other intracellular
signaling components such as PKC, mTOR and cofilin [58]
(Fig. 3d). In normal muscle cells and satellite cells, the
presence of lamin A, emerin, NET25 and MAN modulate
the signals from MAPK and TGFb pathways (also
mTORC1 pathway). When these proteins are mutated or
absent, over activation of effector transcription factors
occurs [103]. Emerin and NET25 have partly overlapping
functions in modulation of ERK1/2 signal transduction
pathway while MAN1 affects both ERK1/2 and TGFb
signaling (the latter through sequestering of Smad proteins)
[137, 166, 168, 169, 171, 252]. Mutations in the gene
coding for MAN1 lead to hyperactivation of this pathway,
which in turn promotes osteoblast differentiation and has
implications for muscle and cardiac fibrosis {Capanni,
2009 #5923) [235].
A-type lamins interact with Smads 2/3, which leads to
the inhibition of TGFb/Smad-dependent transcription. The
underlying cause of this phenomenon is dephosphorylation
of Smads via PP2A kinase, which is promoted by lamins
[167, 235]. EDMD-causing lamin A mutations as well as
absence of lamin A contribute to the alterations in Smads
phosphorylation. Indeed, impaired TGFb/Smad signaling
has been linked with muscle fibrosis in lamin A knockout
mice [235] (Fig. 3d).
mTOR
mTOR pathway integrates inputs from five different
extracellular signals: growth factors, genotoxic stress,
energy status, oxygen and amino acids. mTORC1 activity
is inhibited by TSC1/2 proteins which in turn are inhibited
directly by Akt, RSK1 and ERK1/2 kinases and IKKb
keeping mTORC1 active. GSK3b kinase which branches
the signal from Wnt, activates TSC1/2 thus inhibiting
mTORC1 signaling. Active mTORC1 activates SREBP1
and PPARc (Fig. 3h). Interaction between insulin-like
growth factor II (IGF-II) and the Ser/Thr kinase mamma-
lian target of rapamycin (mTOR, required for IGF-II
expression) participates in the early stage of myogenesis
[68]. This interplay is mediated by NET39, which nega-
tively regulates myogenic differentiation due to its ability
to bind mTOR [132]. This in turn leads to the repression of
IGF-II induction. Since the knockout of NET39 (contrary
to its overexpression) increases mTOR activity and thereby
IGF-II synthesis during early myoblast differentiation, it is
thought that NET39 may sequestrate mTOR at the NE and
act as a part of negative feedback for the regulation of
myogenesis (Fig. 3h). Its synthesis during myogenesis is
regulated by early myogenic regulatory factors such as
MyoD and MEF2. NET39 is highly expressed after myo-
blast differentiation and in mature muscle, which probably
reflects its participation in muscle homeostasis [132]
(Fig. 3h). It is possible, that one of the signaling proteins in
muscles and myoblasts transmitting signal between mTOR,
MAPs and IKKb may be S100B protein [233].
Recent analysis of properties of HGPS cells and prog-
erin indicated that lamin A is involved in pathways
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regulating cellular response to stress and oxidative stress
and the effect of rapamycin on partial restoration of wild
type properties of HGPS cells [87]. The molecular back-
ground of the effect of rapamycin on HGPS cells may be
based on both mTORC1 and mTORC2 complexes. Active
mTORC1 inhibits insulin and IGF signaling and via dif-
ferent pathway activates, together with PGC1 and YY1,
transcription of genes involved in mitochondrial prolifer-
ation and oxidative metabolism. mTORC2 complex acting
through Akt and probably 14-3-3 protein inhibits FOX01
and FOX03a transcription factors regulating stress resis-
tance, apoptosis and metabolism [123, 124] Recent data
indicated that mTORC1 directly stimulates SREBP-1c and
uncouples lipogenesis from gluconeogenesis [123].
Akt signaling
Lamins are linked with PI3 kinase/Akt signaling, which is
necessary for myocyte maturation [246]. Insulin stimula-
tion seems to play a role during muscle development and
regeneration. A-type lamins are phosphorylated at their
N-terminal end by Akt kinase in response to insulin. This
modification is impaired in laminopathic muscles (EDMD
and LGMD1B) [43, 45] (Fig. 3g). Akt phosphorylates
lamin A also at the Ser404 residue, which is reported to be
a putative binding site for 14.3.3 proteins [43]. Moreover,
phosphorylation at this residue has been involved in posi-
tioning of human lamin A [129]. Members of the 14.3.3
family are responsible for modulation of the G2/M phase
transition. They also probably interact with A-type lamins
during mitosis [6]. Indeed Ser404 is identified as phos-
phorylated on soluble lamin A, which seems to support this
thesis. Phosphorylation of lamin A at Ser404 via Akt
kinase may influence lamin A stability and polymerization.
This, in turn, may have an effect on lamin A ability to
interact with other factors playing a role in modulation of
various signaling pathways [43].
Adipogenic program
The central step in the activation of adipogenic program is
expression of peroxisome proliferator-activated receptor
gamma (PPARc), which is the main adipogenic transcrip-
tion factor and strictly depends on the b-catenin level.
Standing activation of b-catenin inhibits PPARc expres-
sion, which results in suppression of adipogenesis. Because
accumulation and stability of b-catenin depend on emerin
(and A-type lamins), it was suggested that emerin level
could be the main factor modulating the balance between
b-catenin and PPARc, hence influencing adipogenesis
[231]. These observations suggest that there is a link
between emerin mutation and the progressive replacement
of skeletal muscle fibers and cardiomyocytes with fatty
fibrotic tissue in patients with X-linked EDMD [7, 231]
(Fig. 3f).
It should be pointed out that hedgehog signaling path-
way when upregulated can induce reprogramming of
myogenic progenitor cells through activation of Pax1 and
inhibition of expression of Pax3 [25–27]. This switches on
the sclerotome development programme. Postnataly
hedgehog pathway may be affected by PKA, GSK3b and
CK1 kinases.
Modulation of chromatin organization and gene
expression
Peripheral regions of the nucleus (with some exceptions)
are thought to be transcriptionally inactive. Lamina-asso-
ciated domains (LADs) mainly created by lamins include
gene-poor regions and help in preservation of the repres-
sive environment. Components of the NL other than lamins
(e.g. LBR, emerin, human LAP2b) due to their participa-
tion in LAD formation also play a role in chromatin
silencing [139, 217]. As indicated recently, Xenopus laevis
XLAP2 isoforms may also contribute to the maintenance
and the anchoring of chromatin domains to the NE and may
participate in formation of lamin B or lamin A microdo-
mains [49]. This seems very plausible since incorporation
of newly synthesized lamins A and B is not uniform and is
accompanied by formation of separate microdomains [76,
217]. Proteins of the INM such as LBR and XLAP2 are
thought to act as a factor critical for stabilization of these
microdomains [49, 141]. Lamins itself can bind chromatin
and DNA in vitro and in vivo [209, 256]. Recent direct
evidences based on studies of HGPS patient cells demon-
strated the involvement of progerin in abnormal chromatin
anchorage, chromosome positioning and chromatin modi-
fication [152].
Silencing at the nuclear periphery is probably locus-
specific and based on locus-specific mediator protein being
able to interact transiently with NL proteins [121]. Tissue-
specific genes that are co-expressed are located in clusters
close to the nuclear periphery. Recent studies confirm that
B-type lamins play an important role in silencing of
multigenic regions and their transcriptional regulation. In
D. melanogaster somatic cells, removal of lamin Dm
results in release of the testis-specific cluster from the NE.
Moreover, activation of the repressed gene cluster seems to
be connected with its displacement from the NE [216].
This phenomenon is of increasing interest to scientists
because it may allow them to explain the underlying
mechanism of differentiation and development in normal
and pathological conditions.
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Studies of Hutchison–Gilford progeria syndrome
(HGPS) and mutated lamin and proteins interacting with
lamins revived and confirmed earlier studies regarding
direct and indirect involvement of lamins and lamin con-
taining complexes in chromatin binding and DNA-binding
in vivo and its effect on chromatin organization and gene
positioning and expression [9, 35, 40, 109, 118, 172, 173].
Lamins and protein complexes containing lamins can affect
transcription via different mechanisms such as chromatin
reorganization through recruitment of heterochromatin
proteins, through recruitment of histone modifying protein
complexes or transcription factors and silencers [261].
Nucleus positioning
Nuclei as well as other organelles are non-randomly posi-
tioned in the cells. The location of the nucleus is precisely
determined within the cell and its disruption may lead to
serious dysfunction and decrease in cell viability [48, 140].
This may be exemplified by the phenomenon occurring in
syncytial muscle cells in which the majority of nuclei are
lined up separately beneath the plasma membrane whereas
a small, distinctive population is clustered beneath the
neuromuscular junction. Clustering is mediated by Syne1
protein responsible for positioning nuclei involved in
synaptic activity due to the transcription of neuromuscular
junction-specific genes (NMJ) in these nuclei [8]. Function
of LINC complex proteins in nucleus positioning and
neuromuscular junctions development has been described
recently by many authors [39, 153, 221, 222, 247].
Many studies have led to the conclusion that there must
be links (responsible for information exchange) between
extracellular matrix constituents such as integrins and
dystroglycan receptors and the cytoskeletal elements actin
and intermediate filaments which in turn join the cyto-
plasmic environment (and thereby indirectly external
milieu) with the nuclear interior [97], mainly via the outer
nuclear membrane, inner nuclear membrane as well as NE
components [232]. These also include nesprins, SUN
domain proteins and lamins—all associated with the LINC
complex. The importance of proper functioning of this
multicomponent bridge, with reference to the muscle
activity, has been well documented—mostly due to the
detailed analysis of abnormalities caused by mutations in
genes coding for its elements and resulting in muscular
dystrophies or other myopathies {Ostlund, 2009 #5147).
It is known that myogenic transcription factors such as
MyoD and myogenin can be induced by mechanical
stimulation of cells (e.g. C2C12) and that this induction is
strictly associated with LINC complex activity [33].
Disruption of the LINC complex in muscle cells affects
their mechanotransduction properties [93]. This is reflected
in, inter alia, changes of nuclear movements and muscle
differentiation. In the case of C2C12 myoblasts, their dif-
ferentiation also can be inhibited by aberration in the LINC
complex. Abnormalities in this structure cause elevation of
stretch-induced myogenic transcription factors (inter alia,
by increase in p38 MAPK phosphorylation and subsequent
augmentation of MyoD and myogenin levels) and inhibits
stretch-induced proliferation). [33] (Fig. 3i).
Furthermore, mechanical stimulation of cells may result
in deformations of the nucleus and thereby lead to genetic
material rearrangements resulting in alteration of tran-
scription factors’ access to the chromatin, thus affecting
gene expression. This scenario seems to be plausible due to
the existence of a microdomain in chromatin supported by
the NE or NL proteins [49, 141, 180, 200, 217].
Nuclear lamina and nuclear envelope proteins
interactions with transcription factors
Lim-domain only 7 (Lmo7) is a transcription factor which
activates expression of emerin and other heart and skeletal
muscle genes. In mice, deletion of the gene coding for Lmo7
causes dystrophic phenotype. Both observations suggest that
Lmo7 may be engaged in the EDMD mechanism by
reduction of expression of emerin or other proteins impor-
tant for muscle functioning [101]. Emerin binds to and
inhibits the activity of Lmo7 [63]. Among genes controlled
by Lmo7, four (CREBBP, NAP1L1, LAP2, RBL2) are mis-
regulated in mice and patients lacking emerin. Lmo7
mediates transduction of mechanical or chemical signals
between the nucleus and cytoplasm due to its association
with the plasma membrane junctional complexes. This
allows Lmo7 to induce the transcriptional response in
cardiomyocytes. An analogical mechanism has been pro-
posed in skeletal muscles, where transcription could be
activated via changes in muscle attachment to the extracel-
lular matrix [15, 101, 194]. Recent studies provide new data
on the functional significance of Lmo7 and emerin interac-
tion during myoblast differentiation [63]. According to the
authors, Lmo7 is necessary for proper C2C12 myoblast
differentiation due to its ability to activate Pax3, MyoD and
Myf5 expression by binding to their promoters. Interactions
between Lmo7 and these promoters are facilitated by its
nucleoplasmic localization. As the differentiation proceeds,
probably via a change in the nuclear transport dynamics,
Lmo7 localizes mainly in the cytoplasm of maturing myo-
tubes. Affinity of emerin to Lmo7 increases, leading to
inhibition of Lmo7 interactions with promoters of genes
engaged in muscle differentiation [63] (Fig. 3b).
Emerin interacts with germ cell-less (GCL), a tran-
scription repressor which inhibits E2F-DP dependent gene
expression by direct binding to the subunit of E2F-DP
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dimer [100, 101, 244]. Another emerin partner, transcrip-
tion factor Btf, may be linked to the EDMD disease
because two mutations in emerin, S54F and D95-99, dis-
rupt their interaction [94]. Emerin can be regulated by
phosphorylation because 13 of its 18 tyrosine residues are
phosphorylated in vivo. Recently three tyrosine kinases,
Her2, Scr and Abl, that control emerin modification were
identified [230]. Human epidermal growth factor receptor 2
(Her2, encoded by the ERBB2 gene) belongs to the epi-
dermal growth factor receptor family. This surface
membrane-bound protein is involved in the signal trans-
duction pathways responsible for tissue growth and
differentiation, including heart and skeletal muscles [176].
Scr and Abl are probably downstream effectors of Her2
directly phosphorylating human emerin [206]. In diseased
heart and skeletal muscles (emerin-deficient), the Her2
signaling pathway is disrupted. These findings may suggest
that emerin plays a role as a downstream effector of Her2
and is a potential integrator of signals from different
pathways [139, 230]. Another LEM domain protein,
LAP2b, is also phosphorylated by Scr and Abl [230].
Moreover, Her2-mediated phosphorylation regulates asso-
ciation of emerin with BAF. It is worth noting that under
normal conditions, skeletal muscle nuclei located beneath
the neuromuscular junction are under the control of neu-
regulin-Her2 signaling, which regulates expression of
genes required for neuromuscular junction integrity.
However, Mejat et al. [154] demonstrated that the neuro-
muscular junctions in AD-EDMD patients and a mouse
model of the disease (H222P) are defective. Mutation of
lamin A, which also takes part in the positioning of the
synaptic nuclei at the neuromuscular junction in muscles,
prevents it from performing its function. Nuclei are mis-
localized at the neuromuscular junction and NMJ-specific
genes are misregulated in both mice and humans [154].
Tifft et al. [230] based on their own and previous find-
ings, proposed the ‘‘disrupted signaling’’ hypothesis for
EDMD diseases, according to which emerin functions as a
signal integrator at the NE taking part in tyrosine kinase
signaling by providing the ‘‘scaffold’’ for Scr targets. These
conclusions were drawn from the observations indicating
that emerin plays a crucial role in the regulation of
b-catenin and Lmo7 activity, and its loss or lack of phos-
phorylation influences JNK, MAPK, integrin, Wnt, TGFb
and fibroblast growth factor receptor 2IIIb (FGFR2IIIb)
signaling pathways [101, 144, 166, 230].
The involvement of other nuclear membrane proteins
in the pathogenesis of EDMD
Besides mutations in genes coding for emerin and lamin A,
also changes in genes encoding nesprin-1 (SYNE1) [194,
195] and nesprin-2 (SYNE2) [259] lead to EDMD. The fact
that these four proteins interact with each other suggests a
common disease mechanism based on disruption of the
nucleo-cytoskeletal junction [12, 21, 32, 122, 242]. In
mice, deletion of genes encoding nesprin-1 and -2 or
overexpression of the KASH domain, which destroys
endogenous LINC complexes, results in, besides the dis-
ruption of nuclear organization, failure of nuclei to cluster
at the neuromuscular junctions [86, 260].
In order to explain the mechanism of EDMD resulting in
nesprin mutations, mice with truncated nesprin-1 lacking
the C-terminal KASH domain have been created [194].
Approximately 50 % of homozygous mice exhibit perinatal
lethality, whereas survivors indicate progressive muscle
weakness (particularly hind limb), gait disturbance and
cardiac defects. All double mutant mice (Syne-1 and Syne-
2 null) died perinatally or immediately after birth due to the
respiratory failure [260] indicating that nesprin-1 and ne-
sprin-2 may partially overlap their structural function and
positioning of nuclei at the neuromuscular junction.
Indeed, during the maturation of myotubes, nesprin-1 is
gradually replaced by nesprin-2 [199]. In cardiac and
skeletal muscles from EDMD patients, as well as in the
mutant mice, components of the LINC complex are not
mislocalized (including truncated nesprin-1a and its bind-
ing partner SUN2). However, the LINC complex displays
abnormalities in association between mutant nesprin-1 and
SUN2. Thus loss of the bridge between the nucleoplasm
and cytoplasm may be the cause of neuromuscular diseases
[194]. Moreover, emerin and short nesprin-2a isoform
(which lacks the KASH domain and is located at the INM
via its associations with lamin A and emerin) are identified
as novel binding’s partners of SUN1 and SUN2 [259].
Interactions of both SUN proteins are perturbed in EDMD
and HGPS. Since SUN1 and SUN2 play critical, but
overlapping functions in anchoring nuclei in skeletal
muscles [127] this may suggest that SUNs also participate
in the development of these diseases [93].
Prospects for treatment
Over the last decade, several reports have been published
on the possible use of small molecules for laminopathy
treatment. Molecular targets for treatment are usually key
enzymes from signaling or metabolic pathways giving rise,
with combination with mutated gene, to specific laminop-
athy. For lipodystrophy, typically leptin or thiazolinidone
(TZD) have been recommended. For HGPS treatment, the
combination of N-containing bisphosphonates, statins and
farnezyl transferaze inhibitors (FTIs) (e.g. tipifarnib, lo-
nafarnib) have been used in clinical trials ([81, 237, 249]
and Progeria Research Foundation webpage).
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Unfortunately both statins and FTIs are likely to cause
significant side effects. FTIs are also modulators of activity
of membrane-bound small GTPases and reportedly induce
‘‘donut-shaped cell nuclei’’—the effect associated with
centrosomes separation defect [238].
Another small molecule: N-acetylcysteine can be used to
prevent the oxidative damage of DNA in progeria HGPS
and other laminopathies since it has been positively tested
in mdx mice model [229].
Recently, rapamycin was positively tested on HGPS
fibroblasts in removal of nuclear blebbing and delaying
cellular senescence [40]. This discovery is especially
interesting because rapamycin affects mTOR signaling
pathway and, among others, modulate IGF-II signaling.
Recently Carlos-Lopez-Otin group introduced recombinant
IGF-1 as a useful treatment for HGPS [147]. Another
possible treatment for laminopathies suggested the use of
histone deacetylase inhibitors (e.g. trichostatin A) [54] and
inhibitors of mitogen activated protein kinases (ERK1-2)
[170] and in general inhibitors of signaling tyrosine kinases
for ‘‘muscular’’ laminopathies. Recently, induced macro-
phagy was suggested as possible treatment for HGPS [44,
87]. Unfortunately, all current pharmacological approaches
to laminopathies did not give satisfactory results and are
not targeted to cure but only to ameliorate the effects and
slow down or stop the disease progression. Perhaps, the
advances made in gene therapy development for other
muscular dystrophies such as Duchene and Becker mus-
cular dystrophy (DMD and BMD) may provide the
solution. For example, N-Acetylcysteine may be used to
prevent the oxidative damage of DNA in progeria HGPS
and other laminopathies since it has been positively tested
in mdx mice model [229].
Transdifferentiation as an alternative method for gen-
eration of muscle cells for patient treatment and research
has also been considered. Several studies have demon-
strated that ectopic expression of MyoD acts as a
reprogramming factor and is sufficient for the transdiffer-
entiation of non-muscle cells such as dermal fibroblasts,
chondroblasts, gizzard smooth muscle, and pigmented
retinal epithelial cells into myoblasts [19]. In addition,
ectopic expression of Pax7 seems to be sufficient to
reprogram ES and iPS cells to muscle progenitor cells [59,
60]. Exogenous MyoD enables muscle formation which is
indiscernible from normal myogenesis with preservation of
steps occurring in vivo and in vitro, including cell cycle
withdrawal, subsequent expression of the proteins involved
in the myogenic program (desmin, a-actinin, titin, troponin
I, a-actin, myosin heavy chain) and fusion of the myoblasts
into multinucleated myotubes (independent of surrounding
extracellular matrix molecules). Activation of myogenesis
leads to down regulation of the original differentiation
program of the converted cell [64]. Transdifferentiation of
various types of cell has been considered as medical
treatment. Application of easy-to-obtain and abundant
cells, especially fibroblasts, as potential therapeutic agents
appears to be an interesting variant in myogenic [106] and
cardiomyogenic diseases [228]. Further investigation of
this absorbing phenomenon may provide us an invaluable
tool to replace damaged tissue.
Recently, reproducible procedures for transdifferentia-
tion have been established starting from somatic cells from
patients with different diseases. Reprogrammed cells, called
induced pluripotent stem cells (iPSCs), also displayed a
particular disease phenotype and thus can be used as a model
for differentiation studies. From the point of view of lam-
inopathies, two iPSC models have been established recently:
for autosomal dominant Emery–Dreifuss muscular dystro-
phy (AD-EDMD) [98] and for Hutchinson–Gilford progeria
syndrome (HGPS) [258]. The major disadvantage of ES and
iPS cells is their potential for cancerogenesis [113].
Adult mesenchymal stem cells (MSCs) that can be iso-
lated from bone marrow appear to be a useful source of
material for tissue transplantation techniques and regener-
ative medicine since they can differentiate into various
tissue types including muscles. The MSCs have a large
capacity for self-renewal and in tissue cultures are able to
maintain their multipotency. Another advantage of the
MSCs is their capacity of secretion of a broad spectrum of
bioactive molecules that ensure a regenerative environment
for various tissues. Some investigations suggest that the
MSCs are a suitable tool for treatment of myocardial
infarcts [42]. Although some reports indicate that myo-
blasts and nuclei from myotubes originated from HSC cells
may not be fully functional with respect to expression of
muscle-specific proteins [50], they may have beneficial
effect by creating stem cell environment and induce
effective regeneration of diseased muscles [90]. It has also
been reported that apart from fibroblasts, human synovial
stem cells (hSSCs) could be considered as an appropriate
agent for clinical applications. These cells display the
ability to regenerate muscle fibers and the reservoir of
satellite cells, features that can be enhanced by ectopic
expression of human MyoD [157]. Although, efficiency of
the muscle regeneration process of hSSCs is not satisfac-
tory, their capacity for expression and secretion of
extracellular matrix components (including laminin a2 and
collagen VI) makes them a useful tool in the search for
treatments to help fight muscular dystrophies [189]. Intra-
muscular transplantation of cells that are able to play a
trophic role may prove to be helpful during the develop-
ment of novel therapies for muscle diseases caused by
deficiencies in their microenvironment [190].
It is hard to imagine at this moment what would be the
future cell and gene therapy for laminopathies. Researchers
still suffer from insufficient knowledge of the molecular
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background of the diseases. Nevertheless, attempts at such
treatment should be made at least on tissue-cultured patient
cells and model organisms. Such attempts can be based on
the current knowledge about cell and gene therapy for other
muscular dystrophies. Especially, Duchene muscular dys-
trophy (DMD) or limb-girdle muscular dystrophy 2E/2F
(LGMD) and experiments on a mice model system for these
diseases (mdx and sgcb-null mice respectively) seem to be
the most optimistic [90, 91]. The strategy for treatment of
autosomal recessive types of laminopathies looks pretty
straightforward; it is only necessary to deliver a wild type
copy of the defective gene into the majority of the myotubes
and provide the proper expression cassette in order to obtain
the desired level of wild type protein expression. Autosomal
dominant diseases, when the mutated protein has the
property of ‘‘negative dominant mutant’’, however, require
a much more complex approach.
Generally, it requires the neutralization of the mutant
allele (protein). This can be done either by the lentivirus
mediated si/shRNA method or homologous recombination
of the mutated genomic sequence with a specially prepared
vector silencing the gene. This strategy may have to be
simultaneously accompanied by insertion of a wild type
allele into the genomic DNA. The si/shRNA method and
homologous recombination/gene editing methods have
been successfully used in HGPS treatment in a tissue cul-
ture model [102, 133, 211]. Recently, induced macrophagy
was suggested as possible treatment for HGPS [44, 87].
Unfortunately, our limited knowledge of the genetic
manipulation of muscle cells in mice and humans renders
gene editing and the homologous recombination approach
of gene therapy technically impossible to apply, mostly due
to the limited efficiency of such procedures in vivo. There
are many different reasons why this is the case. Some of
them originate in the properties of muscles and their
compact structure, the presence of the basal lamina limiting
access to each myotube as well as heterogeneity of cells
and nuclei inside the basal lamina. Other technical limita-
tions lie in difficulty in targeting vectors onto myotubes
and poor efficiency of transfection or transduction of
myotubes. Another set of problems arises from the time
span in which the therapeutic construct is maintained in
myotubes: whether the construct is integrated with geno-
mic DNA, whether the protein is expressed in sufficient
amounts and whether myotubes expressing the wild type
protein are eliminated by the immune system. Another
important technical difficulty is presented when gene
therapy is undertaken on adult subjects. The restoration of
the original mass and efficiency of muscles when muscles
have already been severely damaged by the disease poses a
problem. Specifically, the problem is how to induce
genetically modified satellite cells or side population cells
to proliferate, migrate and restore wasted muscle fibers.
There should be no such problem in young organisms, at
least in the case of mice. There is evidence from mice
models that the earlier gene therapy is intiated, the better
and the more profound are the effects that can be achieved.
This is probably due to the ability to modify a larger
population of satellite cells and newly forming myotubes in
young organisms. Young (developing) muscle tissue may
also be more permeable than adult tissues.
Some published data [156] obtained on mdx and sgcb-null
mice transduced with virus vectors carrying dystrophin and
sarcoglycan genes respectively are very promising. Unfor-
tunately, the mouse model system for dystrophies is not the
best for developing gene therapy for human dystrophies,
mostly due to the vastly different lifespan of mice and
humans and in consequence insufficiently long maintenance
of the therapeutic vector or persistence of modified cells. The
above-mentioned problems encountered by systemic gene
therapy for muscular dystrophies are only a few examples of
the most obvious among many others of varying importance.
Fortunately there are other, theoretically possible strat-
egies for cell and gene therapy treatment for muscular
dystrophies. They are mostly based on ex vivo gene ther-
apy based on the use of muscle satellite cells (or side
population cells), pluripotent mesenchymal stem cells
(MSCs) or hematopoietic stem cells (HSCs), synovial cells
or the use of terminally committed cells such as fibroblasts
reprogrammed by transdifferentiation into MSCs or myo-
blasts [208]. Such strategies although promising, also face
several technical difficulties. It is generally known how to
isolate MSCs or HSCs (CD133?) and differentiate them
into myoblasts in vitro. There is essentially no technical
problem with transfection and transduction of such cells or
with selection and propagation. It is also possible to
transdifferentiation fibroblasts into myoblasts.
The main problems with the ex vivo strategy are asso-
ciated with problems in keeping the stemness of cells and
(especially muscle stem cells) and accessibility of muscles
to such prepared cells. A series of intramuscular microin-
jections is only possible in the case of easily accessible
muscles. Systemic delivery into the blood system requires
the use of an efficient targeting system enabling such cells
to be retained efficiently in muscle blood vessels followed
by migration into the muscle tissues. At this point the
question arises which ex vivo modified cells should be used:
myoblasts, HSCs, MSCs or perhaps synovial cells [3, 4]?
Myoblasts have a significant advantage over HSCs when
direct microinjection into mice heart is analyzed due to the
better migration potential. When systemic delivery is
considered, HSCs appear to have an advantage over any
other cells. Considering all possible strategies of ex vivo
gene therapy for muscular dystrophies, HSCs and MSCs
display a significant advantage over other cells because
they can differentiate into myoblasts and subsequently into
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myotubes, may be easily delivered to damaged tissue or
can be stimulated to differentiate in vitro and then deliv-
ered to patients. Thus, efficient gene therapy for muscular
laminopathy may be based on the isolation of HSCs from
the potential patient, correction of the disease phenotype
and co-transfection with the genes encoding proteins
responsible for differentiation into ‘‘primary’’ myoblasts
such as Shh, Pax7, MyoD, and Sca-1. Obtained cells would
be infused or microinjected back into patients, where they
should differentiate into primary myoblasts and then into
muscle cells, which can repopulate and fuse with existing
myotubes or form new muscles.
Conclusions
Although laminopathies are relatively rare diseases com-
paring to Duchenne or Becker muscular dystrophy (DMD),
investigations of these abnormalities may bring valuable
information about general processes occurring in cells
under normal (e.g. physiological ageing) as well as path-
ological conditions such as muscular dystrophies.
A better understanding of mechanisms leading to dis-
eases may contribute to discovery of novel therapies.
Recent studies suggest some solutions that could be used as
medical treatment. For example, improvement of differ-
entiation in C2C12 myoblasts expressing R453W mutant
lamin A is possible after pharmacological inhibition of the
MAPK pathway [71]. An earlier study proposed another
way of increasing the differentiation potential of lamin
A-null myoblasts by providing them with exogenously
expressed desmin or MyoD [75].
Also, development of an application using transdiffer-
entiation of donor engineered cells may prove to be an
invaluable tool for treatment of various dystrophic
diseases.
Experiments undertaken over the last 10 years have
shown that we are at the beginning of understanding the role
that NE proteins play in the complex network regulating cell
function. Comprehension of all molecular connections is a
great challenge. However, the tangled web of mutual rela-
tions is an obstacle hindering explanation of the mechanisms
underlying the development of laminopathies.
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